Citations

Clear

19 citation(s) found for "Park, David".

Year in Review in Cardiac Electrophysiology
Hussein, Ayman A. , Madhavan, Malini , Viswanathan, Mohan , Ceresnak, Scott R. , Park, David , Wang, Paul J. , Park, David S , Tzou, Wendy S. , Steinberg, Benjamin A. , Davis, Darryl Raymond , Kapa, Suraj

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | February 12, 2019 | Volume: 12 | Issue: 2 | Pages: No page available

10.1161/circep.118.007142 | PMID 30744401 Get It

Abstract 4995: Identity fraud: Lineage plasticity as a mechanism of anti-androgen resistance and target for therapy
Davies, Alastair , Bostock, Chiara , Ahmed, Musaddeque , Lin, Yen‐Yi , Johnson, Fraser , Nip, Ka Mun , Ketola, Kirsi , Bishop, Jennifer L. , Fazli, Ladan , Goodrich, David C., He, Hansen, Beltran, Himisha , Zoubeidi, Amina , Ahmed, Musaddeque , Huang, Haojie , Goodrich, David, Hach, Faraz

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 4995-4995

10.1158/1538-7445.am2018-4995 Get It

Abstract Background: Potent targeting of the androgen receptor (AR) in castration-resistant prostate cancer has altered the archetypal course of the disease, fueling the emergence of aggressive and incurable neuroendocrine prostate cancer (NEPC). Recent evidence suggests that these tumors can arise from non-neuroendocrine cells in response to AR pathway inhibitors (ARPIs), such as enzalutamide (ENZ), an observation consistent with lineage plasticity. What regulates this plasticity that allows cells to shed their dependence on the AR and re-emerge as “AR-indifferent” NEPC? Sequencing studies have uncovered that the evolution toward a NEPC phenotype is aligned with dynamic epigenetic reprogramming, but the molecular basis underlying this phenomenon remains poorly understood. Methods: We developed an in vivo model of acquired ENZ resistance to (a) identify reprogramming factors that facilitate lineage plasticity, and (b) determine how to best capitalize on therapeutic strategies aimed at blocking or reversing lineage transformation. Cell lines derived from ENZ-resistant tumors were profiled by RNA-seq and ChIP-seq, and functionally assessed for stem cell-associated properties. Our findings were validated across NEPC cell lines (NCI-H660), genetically engineered mouse models (PBCre4:Ptenf/f:Rb1f/f), and patient tumors and organoids. CRISPR/Cas9-mediated genomic editing allowed us to assess the effect of knocking out reprogramming factors on therapy-induced neuroendocrine transdifferentiation. Results: AR-indifferent ENZ-resistant tumors were enriched for a Polycomb/EZH2 signature; in particular, we identified EZH2 to be phosphorylated at threonine-350 (pEZH2-T350) by CDK1 in NEPC cell lines, mouse models, and patient tumors. Accordingly, RB1 loss was sufficient to enhance pEZH2-T350, which was required for prostate cancer cells to convert to a metastable stem-like state and, in turn, acquire neuroendocrine features under the pressure of ARPIs both in vitro and in patient-derived xenografts. This therapy-induced NEPC transdifferentation was associated with a marked redistribution of EZH2 and H3K27me3, specifically to a core set of genes governing lineage identity. AR colocalized at the reprogrammed EZH2 binding sites, and was found to be part of the same complex with EZH2. Treating AR-indifferent/NEPC cell lines with clinically relevant EZH2 inhibitors reversed the lineage switch and mitigated ENZ resistance. Conclusions: This research establishes the centrality of epigenetic reprogramming in driving the insurgence of a neuroendocrine phenotype in response to ARPIs, and posits that drugging the epigenome via EZH2 inhibition may reverse or delay lineage transformation to extend the durability of clinically beneficial ARPIs. Citation Format: Alastair H. Davies, Chiara Bostock, Musaddeque Ahmed, Yen-Yi Lin, Fraser Johnson, Ka Mun Nip, Kirsi Ketola, Jennifer Bishop, Ladan Fazli, Haojie Huang, David Goodrich, Faraz Hach, Hansen He, Himisha Beltran, Amina Zoubeidi. Identity fraud: Lineage plasticity as a mechanism of anti-androgen resistance and target for therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4995.
Year in Review in Cardiac Electrophysiology
Park, David , Viswanathan, Mohan , Madhavan, Malini , Ceresnak, Scott R. , Wang, Paul J. , Kapa, Suraj , Park, David S , Davis, Darryl Raymond , Steinberg, Benjamin A. , Tzou, Wendy S.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 16, 2018 | Volume: 11 | Issue: 7 | Pages: No page available

10.1161/circep.118.006648 | PMID 30012874 Get It

Smoking, Sex, and Non–Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424)
Darke, Amy K. , Zirpoli, Gary , Davis, Warren , Ondracek, Rochelle Payne , Bshara, Wiam , Omilian, Angela R. , Kratzke, Robert A. , Reid, Mary E. , Molina, Julian R. , Chen, Yuhchyau , MacRae, Robert M. , Gandara, David R. , Kelly, Karen , Santella, Regina M. , Albain, Kathy S. , Kelly, Karen , Cheng, Ting‐Yuan David , Redman, Mary W. , Kolesar, Jill , Moon, James , Mack, Philip C. , Ambrosone, Christine B. , Zirpoli, Gary , Gandara, David

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 13, 2017 | Volume: 110 | Issue: 7 | Pages: 734-742

10.1093/jnci/djx260 | PMID 29346580 Get It

TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup
Labbé, David P. , Sweeney, Christopher J. , Galbo, Phillip M. , Wadosky, Kristine M. , Ku, Sheng‐Yu , Sjöström, Martin , Alshalalfa, Mohammed , Erho, Nicholas , Karnes, R. Jeffrey , Schaeffer, Edward M. , Jenkins, Robert B. , Ross, Ashley E. , Bowden, Michaela , Huang, Ying , Gray, Kathryn P. , Feng, Felix Y. , Spratt, Daniel E. , Goodrich, David W. , Ellis, Leigh , Spratt, Daniel E , Sweeney, Christopher , Brown, Myles , Rosario, Spencer R. , Davicioni, Elai , Den, Robert B. , Eng, Kevin H.

Mayo Clinic

Clinical Cancer Research | September 12, 2017 | Volume: 23 | Issue: 22 | Pages: 7072-7083

10.1158/1078-0432.ccr-17-0413 | PMID 28899973 Get It

Abstract Purpose: Current clinical parameters do not stratify indolent from aggressive prostate cancer. Aggressive prostate cancer, defined by the progression from localized disease to metastasis, is responsible for the majority of prostate cancer–associated mortality. Recent gene expression profiling has proven successful in predicting the outcome of prostate cancer patients; however, they have yet to provide targeted therapy approaches that could inhibit a patient's progression to metastatic disease. Experimental Design: We have interrogated a total of seven primary prostate cancer cohorts (n = 1,900), two metastatic castration-resistant prostate cancer datasets (n = 293), and one prospective cohort (n = 1,385) to assess the impact of TOP2A and EZH2 expression on prostate cancer cellular program and patient outcomes. We also performed IHC staining for TOP2A and EZH2 in a cohort of primary prostate cancer patients (n = 89) with known outcome. Finally, we explored the therapeutic potential of a combination therapy targeting both TOP2A and EZH2 using novel prostate cancer–derived murine cell lines. Results: We demonstrate by genome-wide analysis of independent primary and metastatic prostate cancer datasets that concurrent TOP2A and EZH2 mRNA and protein upregulation selected for a subgroup of primary and metastatic patients with more aggressive disease and notable overlap of genes involved in mitotic regulation. Importantly, TOP2A and EZH2 in prostate cancer cells act as key driving oncogenes, a fact highlighted by sensitivity to combination-targeted therapy. Conclusions: Overall, our data support further assessment of TOP2A and EZH2 as biomarkers for early identification of patients with increased metastatic potential that may benefit from adjuvant or neoadjuvant targeted therapy approaches. Clin Cancer Res; 23(22); 7072–83. ©2017 AACR.
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Poznak, Catherine Van , Somerfield, Mark R. , Bast, Robert C. , Cristofanilli, Massimo , González-Angulo, Ana M. , Hicks, David G., Hill, Elizabeth G. , Liu, Minetta C. , Lucas, Wanda, Mennel, Robert, Symmans, W. Fraser , Hayes, Daniel F. , Harris, Lyndsay N. , Van Poznak, Catherine, Mayer, Ingrid A. , Mennel, Robert G, Symmans, William F, Goetz, Matthew P. , Bast, Robert C , Symmans, W Fraser , Cristofanilli, Massimo

Mayo Clinic

Journal of Clinical Oncology | July 20, 2015 | Volume: 33 | Issue: 24 | Pages: 2695-2704

10.1200/jco.2015.61.1459 | PMID 26195705 Get It

Purpose To provide recommendations on the appropriate use of breast tumor biomarker assay results to guide decisions on systemic therapy for metastatic breast cancer. Methods A literature search and prospectively defined study selection identified systematic reviews, meta-analyses, randomized controlled trials (RCTs), prospective–retrospective studies, and prospective comparative observational studies published from 2006 through September 2014. Results The literature search revealed 17 articles that met criteria for further review: 11 studies reporting discordances between primary tumors and metastases in expression of hormone receptors or human epidermal growth factor receptor 2 (HER2), one RCT that addressed the use of a biomarker to decide whether to change or continue a treatment regimen, and five prospective–retrospective studies that evaluated the clinical utility of biomarkers. Recommendations In patients with accessible metastases, biopsy for confirmation of disease process and retesting of estrogen receptor, progesterone receptor, and HER2 status should be offered, but evidence is lacking to determine whether changing anticancer treatment on the basis of change in receptor status affects clinical outcomes. With discordance of results between primary and metastatic tissues, the Panel consensus is to use preferentially the estrogen receptor, progesterone receptor, and HER2 status of the metastasis to direct therapy if supported by the clinical scenario and patient's goals for care. Carcinoembryonic antigen, cancer antigen 15-3, and cancer antigen 27-29 may be used as adjunctive assessments, but not alone, to contribute to decisions regarding therapy. Recommendations for tumor rebiopsy and use of circulating tumor markers are based on clinical experience and Panel informal consensus in the absence of studies designed to evaluate the clinical utility of the markers. As such, it is also reasonable for clinicians to not use these markers as adjunctive assessments.
Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
Konecny, Gottfried E. , Pegram, Mark D. , Venkatesan, Natarajan , Yang, Guorong , Rahmeh, Martina, Rusnak, David W., Spehar, Glenn, Mullin, Robert J., Keith, Barry R., Gilmer, Tona M. , Berger, Mark S., Podratz, Karl C. , Slamon, Dennis J. , Finn, Richard S. , Untch, Michael

Mayo Clinic

Cancer Research | February 1, 2006 | Volume: 66 | Issue: 3 | Pages: 1630-1639

10.1158/0008-5472.can-05-1182 | PMID 16452222 Get It

Abstract Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. Here, we explore the therapeutic potential of lapatinib by testing its effect on tumor cell growth in a panel of 31 characterized human breast cancer cell lines, including trastuzumab-conditioned HER-2-positive cell lines. We further characterize its activity in combination with trastuzumab and analyze whether EGFR and HER-2 expression or changes induced in the activation of EGFR, HER-2, Raf, AKT, or extracellular signal-regulated kinase (ERK) are markers of drug activity. We report that concentration-dependent antiproliferative effects of lapatinib were seen in all breast cancer cell lines tested but varied significantly between individual cell lines with up to 1,000-fold difference in the IC50s (range, 0.010-18.6 μmol/L). Response to lapatinib was significantly correlated with HER-2 expression and its ability to inhibit HER-2, Raf, AKT, and ERK phosphorylation. Long-term in vivo lapatinib studies were conducted with human breast cancer xenografts in athymic mice. Treatment over 77 days resulted in a sustained and significant reduction in xenograft volume compared with untreated controls. For the combination of lapatinib plus trastuzumab, synergistic drug interactions were observed in four different HER-2-overexpressing cell lines. Moreover, lapatinib retained significant in vitro activity against cell lines selected for long-term outgrowth (>9 months) in trastuzumab-containing (100 μg/mL) culture medium. These observations provide a clear biological rationale to test lapatinib as a single agent or in combination with trastuzumab in HER-2-overexpressing breast cancer and in patients with clinical resistance to trastuzumab. (Cancer Res 2006; 66(3): 1630-9)
Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist “Trigger”
Aquino, Christopher, Armour, Duncan, Berman, Judd, Birkemo, Larry S., Carr, Robin A. E., Croom, Dallas K., Dezube, Milana, Dougherty, R. W., Ervin, Gregory N., Grizzle, Mary K., Head, Julie E., Hirst, Gavin C. , James, Michael K. , Johnson, Michael F., Queen, Kennedy L., Rimele, Thomas J., Smith, David Norman , Sugg, Elizabeth E., Miller, Laurence J.

Mayo Clinic

Journal of Medicinal Chemistry | July 26, 2002 | Volume: 39 | Issue: 2 | Pages: 562-569

10.1021/jm950626d | PMID 8558528 Get It